Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1960 1
1961 2
1964 3
1965 3
1966 10
1967 1
1968 12
1969 3
1970 4
1971 4
1972 6
1973 3
1974 7
1975 6
1976 10
1977 13
1978 15
1979 10
1980 16
1981 20
1982 18
1983 17
1984 8
1985 19
1986 7
1987 10
1988 9
1989 14
1990 12
1991 9
1992 8
1993 8
1994 7
1995 6
1996 10
1997 9
1998 3
1999 5
2000 10
2001 6
2002 7
2003 6
2004 8
2005 12
2006 13
2007 15
2008 10
2009 11
2010 16
2011 19
2012 13
2013 18
2014 23
2015 21
2016 9
2017 8
2018 7
2019 8
2020 8
2021 7
2022 5
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

568 results

Results by year

Filters applied: . Clear all
Page 1
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Adams D, et al. Among authors: dyck pj. N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153. N Engl J Med. 2018. PMID: 29972753 Free article. Clinical Trial.
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T. Benson MD, et al. Among authors: dyck pj. N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793. N Engl J Med. 2018. PMID: 29972757 Free article. Clinical Trial.
Toxic Neuropathies.
Karam C, Dyck PJ. Karam C, et al. Among authors: dyck pj. Semin Neurol. 2015 Aug;35(4):448-57. doi: 10.1055/s-0035-1558977. Epub 2015 Oct 6. Semin Neurol. 2015. PMID: 26502767 Review.
Vasculitic neuropathies.
Gwathmey KG, Burns TM, Collins MP, Dyck PJ. Gwathmey KG, et al. Among authors: dyck pj. Lancet Neurol. 2014 Jan;13(1):67-82. doi: 10.1016/S1474-4422(13)70236-9. Lancet Neurol. 2014. PMID: 24331794 Review.
Diabetic radiculoplexus neuropathies.
Laughlin RS, Dyck PJ. Laughlin RS, et al. Among authors: dyck pj. Handb Clin Neurol. 2014;126:45-52. doi: 10.1016/B978-0-444-53480-4.00004-7. Handb Clin Neurol. 2014. PMID: 25410213 Review.
Vasculitic neuropathies.
Burns TM, Schaublin GA, Dyck PJ. Burns TM, et al. Among authors: dyck pj. Neurol Clin. 2007 Feb;25(1):89-113. doi: 10.1016/j.ncl.2006.11.002. Neurol Clin. 2007. PMID: 17324722 Review.
568 results